On September 25th, the list of “2023 Shenzhen Top 500 Enterprises” was officially announced. With outstanding performance in terms of overall scale, operating efficiency, creative capabilities and other comprehensive strengths, Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) was once again selected, ranking 143rd on the list. Shenzhen Kangzhe was also listed on the “Top 100 Social Contribution List of 2023 Shenzhen Top 500 Enterprises”. The “2023 Shenzhen Top 500 Enterprises” list is jointly released by the Shenzhen Enterprise Federation and Shenzhen Entrepreneurs’ Association. It is one of the most influential and authoritative rankings for Shenzhen enterprises. The list primarily evaluates participating companies based on various production and operation indicators where all the listing companies are the backbone of Shenzhen’s economic and social development. Due to Shenzhen’s rapid economic growth and the Group’s solid operational achievements, Shenzhen Kangzhe has been […]
Learn More
Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The Product has a clear mechanism of action, which is conducive to exerting brain cytoprotection effects. Meanwhile, the Product has a rapid anti-depression and anti-anxiety function, and is expected to become the first new type of brain cytoprotectant that treats both stroke and post-stroke depression. The product will enrich the cardio-cerebrovascular (including the central nervous system) pipeline of the Group. After approved for marketing in China, it is expected to meet the clinical needs of drug with both safety and efficacy, providing new treatment options to ischemic stroke patients in China. On August 24, China Medical System Holdings Limited (“CMS” or the “Group”) announced that the Group entered into a Collaboration Agreement (the “Agreement”) with Nanjing NeuroDawn Pharmaceutical Co. Ltd. (“NeuroDawn Pharmaceutical”), for anti-ischemic stroke brain cytoprotectant […]
Learn More